NATURAL HISTORY OF PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: HOW DOES 1-YEAR PROTEINURIA CORRELATE WITH LONG-TERM RENAL OUTCOME?

https://storage.unitedwebnetwork.com/files/1099/f1c66e5cf504dc0a43c71eaba8b38b46.pdf
NATURAL HISTORY OF PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: HOW DOES 1-YEAR PROTEINURIA CORRELATE WITH LONG-TERM RENAL OUTCOME?
Maddalena
Marasa
Giliane Nanchen giliane.nanchen@hotmail.com Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Maddalena Marasa' maddalena.marasa@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Matteo Breno matteo.breno@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Carolina Martinatto carolina.martinatto@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Miriam Rigoldi miriam.rigoldi@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Marina Noris marina.noris@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Elena Bresin elena.bresin@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Sara Gamba sara.gamba@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Laura Bottanelli laura.bottanelli@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Zahra Imanifard zahra.imanifard@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Rossella Piras rossella.piras@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Roberta Donadelli roberta.donadelli@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Ariela Benigni ariela.benigni@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Giuseppe Remuzzi giuseppe.remuzzi@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)
Erica Daina erica.daina@marionegri.it Istituto di Ricerche Farmacologiche Mario Negri Clinical Research Center for Rare Diseases Aldo e Cele Dacco' Ranica (Bergamo)

Membranoproliferative glomerulonephritis (MPGN) is a rare chronic nephropathy, affecting predominantly children and young adults and defined by a typical glomerular histopathological pattern of mesangial hypercellularity, endocapillary proliferation and duplication of the glomerular basement membrane. While clinical presentation and outcome are variable, the overall prognosis is poor, with progression to end-stage renal disease (ESRD) in about 40% of cases.

The aim of the present work was to study the natural history of primary MPGN and to explore the relationship between proteinuria at one year after diagnosis and renal outcome.

Subjects with a histological diagnosis of MPGN were selected from the Italian Registry of MPGN. Secondary forms were excluded.

Parameters were collected at disease onset, at baseline (defined as the time of the first diagnostic biopsy), at 1-year follow-up (with an accepted range of 6 to 18 months) and at the last available follow-up. ESRD was defined by either an estimated glomerular filtration rate (eGFR) below 15 ml/min/1.73m2, dialysis initiation or preemptive kidney transplantation.

For the primary analysis, we excluded subjects with:

-       Follow-up < 6 months after baseline

-       ESRD before baseline or < 6 months thereafter

-       Complement inhibition initiation < 6 months after baseline

-       Missing 24h-proteinuria data at 1-year follow-up

-       Missing eGFR at last available follow-up

The primary outcome was the correlation between 24h-proteinuria at one year after baseline and eGFR at last follow-up. eGFR in subjects in dialysis was considered 15 ml/min/1.73m2.


Table 1a and 1b: full cohort description

In conclusion, this study on patients with idiopathic MPGN selected from the Italian Registry of MPGN demonstrated a negative correlation between quantitative proteinuria at one year and long-term renal function. These findings support the possibility of considering proteinuria reduction as a predictor of long-term renal outcome.

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos